Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy

Xuesong Li, Dong Fang, Matthew R. Cooperberg, Jared M Whitson, Tom F. Lue, Liqun Zhou, Katsuto Shinohara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To investigate variation in the International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. Methods: From January 2004 to November 2009, 524 consecutive patients underwent prostate brachytherapy either alone or in combination with external beam radiation therapy for T1c-T3b prostate cancer. The IPSS was assessed preimplant and at 1, 6, 12, 24, 36, and 48 months after treatment. Clinical and treatment-related factors were assessed for correlations with the IPSS increase. Results: The mean preimplant IPSS was 7.4, with the greatest mean score of 16.0 at 1 month. At 6 months, the mean total IPSS had decreased to 11.5, but it was still statistically significantly greater than that at baseline (<0.001). At 12 months, the IPSS was decreased to 8.6, slightly greater than baseline (p = 0.001). The IPSS of 45.4 % (69/152) patients gradually returned to preimplant levels and that of 71.1 % (108/152) patients returned to within 3 points of the baseline at 24 months. At 24, 36, and 48 months after seed implantation, the IPSS was 8.6, 7.7, and 8.2, respectively, and none of these values differed statistically significantly from baseline (p > 0.05). Sixteen patients (3.1 %) showed AUR, and 11 patients required catheterization. On univariate and multivariate analyses, the IPSS increase was best predicted by lower preimplant IPSS. Conclusion: In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 24 months. The IPSS increase was best predicted by lower preimplant IPSS.

Original languageEnglish (US)
Pages (from-to)1061-1066
Number of pages6
JournalWorld Journal of Urology
Volume32
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Brachytherapy
Prostate
Catheterization
Prostatic Neoplasms
Radiotherapy
Multivariate Analysis

Keywords

  • Brachytherapy
  • Follow-up
  • IPSS
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Li, X., Fang, D., Cooperberg, M. R., Whitson, J. M., Lue, T. F., Zhou, L., & Shinohara, K. (2014). Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World Journal of Urology, 32(4), 1061-1066. https://doi.org/10.1007/s00345-013-1188-y

Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. / Li, Xuesong; Fang, Dong; Cooperberg, Matthew R.; Whitson, Jared M; Lue, Tom F.; Zhou, Liqun; Shinohara, Katsuto.

In: World Journal of Urology, Vol. 32, No. 4, 2014, p. 1061-1066.

Research output: Contribution to journalArticle

Li, X, Fang, D, Cooperberg, MR, Whitson, JM, Lue, TF, Zhou, L & Shinohara, K 2014, 'Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy', World Journal of Urology, vol. 32, no. 4, pp. 1061-1066. https://doi.org/10.1007/s00345-013-1188-y
Li, Xuesong ; Fang, Dong ; Cooperberg, Matthew R. ; Whitson, Jared M ; Lue, Tom F. ; Zhou, Liqun ; Shinohara, Katsuto. / Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. In: World Journal of Urology. 2014 ; Vol. 32, No. 4. pp. 1061-1066.
@article{2f36c6d33b774522af91080e6ef58096,
title = "Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy",
abstract = "Objective: To investigate variation in the International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. Methods: From January 2004 to November 2009, 524 consecutive patients underwent prostate brachytherapy either alone or in combination with external beam radiation therapy for T1c-T3b prostate cancer. The IPSS was assessed preimplant and at 1, 6, 12, 24, 36, and 48 months after treatment. Clinical and treatment-related factors were assessed for correlations with the IPSS increase. Results: The mean preimplant IPSS was 7.4, with the greatest mean score of 16.0 at 1 month. At 6 months, the mean total IPSS had decreased to 11.5, but it was still statistically significantly greater than that at baseline (<0.001). At 12 months, the IPSS was decreased to 8.6, slightly greater than baseline (p = 0.001). The IPSS of 45.4 {\%} (69/152) patients gradually returned to preimplant levels and that of 71.1 {\%} (108/152) patients returned to within 3 points of the baseline at 24 months. At 24, 36, and 48 months after seed implantation, the IPSS was 8.6, 7.7, and 8.2, respectively, and none of these values differed statistically significantly from baseline (p > 0.05). Sixteen patients (3.1 {\%}) showed AUR, and 11 patients required catheterization. On univariate and multivariate analyses, the IPSS increase was best predicted by lower preimplant IPSS. Conclusion: In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 24 months. The IPSS increase was best predicted by lower preimplant IPSS.",
keywords = "Brachytherapy, Follow-up, IPSS, Prostate cancer",
author = "Xuesong Li and Dong Fang and Cooperberg, {Matthew R.} and Whitson, {Jared M} and Lue, {Tom F.} and Liqun Zhou and Katsuto Shinohara",
year = "2014",
doi = "10.1007/s00345-013-1188-y",
language = "English (US)",
volume = "32",
pages = "1061--1066",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy

AU - Li, Xuesong

AU - Fang, Dong

AU - Cooperberg, Matthew R.

AU - Whitson, Jared M

AU - Lue, Tom F.

AU - Zhou, Liqun

AU - Shinohara, Katsuto

PY - 2014

Y1 - 2014

N2 - Objective: To investigate variation in the International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. Methods: From January 2004 to November 2009, 524 consecutive patients underwent prostate brachytherapy either alone or in combination with external beam radiation therapy for T1c-T3b prostate cancer. The IPSS was assessed preimplant and at 1, 6, 12, 24, 36, and 48 months after treatment. Clinical and treatment-related factors were assessed for correlations with the IPSS increase. Results: The mean preimplant IPSS was 7.4, with the greatest mean score of 16.0 at 1 month. At 6 months, the mean total IPSS had decreased to 11.5, but it was still statistically significantly greater than that at baseline (<0.001). At 12 months, the IPSS was decreased to 8.6, slightly greater than baseline (p = 0.001). The IPSS of 45.4 % (69/152) patients gradually returned to preimplant levels and that of 71.1 % (108/152) patients returned to within 3 points of the baseline at 24 months. At 24, 36, and 48 months after seed implantation, the IPSS was 8.6, 7.7, and 8.2, respectively, and none of these values differed statistically significantly from baseline (p > 0.05). Sixteen patients (3.1 %) showed AUR, and 11 patients required catheterization. On univariate and multivariate analyses, the IPSS increase was best predicted by lower preimplant IPSS. Conclusion: In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 24 months. The IPSS increase was best predicted by lower preimplant IPSS.

AB - Objective: To investigate variation in the International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. Methods: From January 2004 to November 2009, 524 consecutive patients underwent prostate brachytherapy either alone or in combination with external beam radiation therapy for T1c-T3b prostate cancer. The IPSS was assessed preimplant and at 1, 6, 12, 24, 36, and 48 months after treatment. Clinical and treatment-related factors were assessed for correlations with the IPSS increase. Results: The mean preimplant IPSS was 7.4, with the greatest mean score of 16.0 at 1 month. At 6 months, the mean total IPSS had decreased to 11.5, but it was still statistically significantly greater than that at baseline (<0.001). At 12 months, the IPSS was decreased to 8.6, slightly greater than baseline (p = 0.001). The IPSS of 45.4 % (69/152) patients gradually returned to preimplant levels and that of 71.1 % (108/152) patients returned to within 3 points of the baseline at 24 months. At 24, 36, and 48 months after seed implantation, the IPSS was 8.6, 7.7, and 8.2, respectively, and none of these values differed statistically significantly from baseline (p > 0.05). Sixteen patients (3.1 %) showed AUR, and 11 patients required catheterization. On univariate and multivariate analyses, the IPSS increase was best predicted by lower preimplant IPSS. Conclusion: In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 24 months. The IPSS increase was best predicted by lower preimplant IPSS.

KW - Brachytherapy

KW - Follow-up

KW - IPSS

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84904876634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904876634&partnerID=8YFLogxK

U2 - 10.1007/s00345-013-1188-y

DO - 10.1007/s00345-013-1188-y

M3 - Article

C2 - 24141807

AN - SCOPUS:84904876634

VL - 32

SP - 1061

EP - 1066

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -